MarginsXMarginsX
Home › Markets › Health Care › AKBA

Akebia Therapeutics Inc. (AKBA)

AKBA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.4486
-5.40% on the day
Market cap
$124.6M
Micro cap
Revenue · 2025
$236.2M
+47.5% on 2024
Net income · 2025
-$5.3M
-2.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/0001517022-26-000020-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAKBA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001517022
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$236.2M
Net income-$5.3M
Operating income$23.5M
Net margin-2.3%
Operating margin9.9%
Revenue growth+47.5%
Cash$184.8M
Total assets$376.6M
P/E (computed)Net income was not positive
P/S (computed)0.5×

Warning signs

Cash runway
Cash-flow positive
$159.3M cash at September 30, 2026
Share count, 1 year
+4.6%
2025-11-04 to 2026-11-02 · +47.4% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$876K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$159.3M cash; operating cash flow $3.9M a quarter.Report 2026-09-30
Shares outstanding277,663,875 (2026-11-02); 265,365,993 a year earlier; 188,389,415 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-10-23
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $87K, sold $963K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$36.9M-$14.4M$2.3M$159.3M$50.3M$197.2M10-Q 2026-11-05
Q2 2026
2026-06-30
$49.1M-$8.9M$3.5M$155.5M$49.6M$219.1M10-Q 2026-08-05
Q1 2026
2026-03-31
$53.5M-$9.1M-$21.2M$162.6M$48.9M$232.4M10-Q 2026-05-07
Q4 2025
2025-12-31
$57.6M-$12.2M$31.1M$184.8M$48.3M$236.2M10-K 2026-02-26
Q3 2025
2025-09-30
$58.8M$540K$28.1M$166.4M$47.6M$225.1M10-Q 2026-11-05
Q2 2025
2025-06-30
$62.5M$247K$22.3M$137.3M$47.1M$203.7M10-Q 2026-08-05
Q1 2025
2025-03-31
$57.3M$6.1M-$13.6M$113.4M$46.5M$184.9M10-Q 2026-05-07
Q4 2024
2024-12-31
$46.5M-$22.8M-$4.5M$51.9M$38.7M$160.2M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-03-20
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 887 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+18.2%
1 month-38.4%
3 months-45.5%
Year to date-70.6%
1 year-73.1%
From 52-week high-73.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ALXOALX Oncology Holdings Inc.$1.00-3.85%$124.9M
SPRBSpruce Biosciences Inc.$42.25-2.45%$121.4M
CNTNCanton Strategic Holdings Inc.$1.64-4.09%$130.7M
NTHINeOnc Technologies Holdings Inc.$4.54-7.54%$131.0M
UPBUpstream Bio Inc.$2.15-22.66%$117.8M
MENSJyong Biotech Ltd.$1.77+0.57%$134.6M
IMUXImmunic Inc.$7.23-3.86%$114.8M
PDSBPDS Biotechnology Corporation$0.9241+5.90%$113.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier